The impact of preadmission oral bisphosphonate use on 30-day mortality following stroke: a population-based cohort study of 100,043 patients.
OBJECTIVE
Bisphosphonate use has been associated with increased risk of fatal stroke. We examined the association between preadmission use of oral bisphosphonates and 30-day mortality following hospitalization for stroke.


METHODS
We conducted a nationwide population-based cohort study using medical databases and identified all patients in Denmark with a first-time hospitalization for stroke between 1 July 2004 and 31 December 2012 (N=100,043). Cox regression was used to compute adjusted hazard ratios as a measure of 30-day mortality rate ratios (MRRs) associated with bisphosphonate current use (prescription filled within 90 days prior to the stroke) or recent use (prescription filled in the 90-180 days prior to the stroke). Current use was further classified as new or long-term use.


RESULTS
We found 51,982 patients with acute ischemic stroke (AIS), 11,779 with intracerebral hemorrhage (ICH), 4,528 with subarachnoid hemorrhage (SAH), and 31,754 with unspecified stroke. Absolute 30-day mortality risks were increased among current vs nonusers of bisphosphonates for AIS (11.9% vs 8.5%), ICH (43.2% vs 34.5%), SAH (40.3% vs 23.2%), and unspecified strokes (18.8% vs 14.0%). However, in adjusted analyses, current bisphosphonate use did not increase 30-day mortality from AIS (MRR, 0.87; 95% confidence interval [CI]: 0.75, 1.01); ICH (MRR, 1.05; 95% CI: 0.90, 1.23); SAH (MRR, 1.15; 95% CI: 0.83, 1.61); or unspecified stroke (MRR, 0.94; 95% CI: 0.81, 1.09). Likewise, no association with mortality was found for recent use. Adjusted analyses by type of bisphosphonate showed increased mortality following stroke among new users of etidronate (MRR, 1.40; 95% CI: 1.01, 1.93) and reduced mortality after AIS among current users of alendronate (MRR, 0.87; 95% CI: 0.74, 1.02).


CONCLUSIONS
We found no overall evidence that preadmission bisphosphonate use increases 30-day mortality following stroke.
Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark ; Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark.
Diana Hedevang
DH
Christensen
Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.
Erzsébet
E
Horváth-Puhó
Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.
Morten
M
Schmidt
Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.
Christian Fynbo
CF
Christiansen
Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.
Lars
L
Pedersen
Department of Endocrinology and Internal Medicine, Aarhus University Hospital, Aarhus, Denmark.
Bente Lomholt
BL
Langdahl
Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.
Reimar Wernich
RW
Thomsen
cardiovascular disease; mortality; oral bisphosphonates; osteoporosis treatment; prognosis; stroke